Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo

1. Conrad, D.H. Fc epsilon RII/CD23: The low Affinity receptor for IgE. Annu. Rev. Immun. 8, 623−645 (1990).
2. Delespesse, G. et al. Expression, structure, and function of the CD23 antigen. Adv. Immun. 49, 149−191 (1991).
3. Bonnefoy, J.Y. et al. Receptors for IgE. Curr. Opin. Immun. 5, 944−949 (1993).
4. Lecoanet-Henchoz, S. et al. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD lib/CD 18 and CDllc/CD18. Immunity (in the press).
5. Herbelin, A., Elhadad, S., Ouaaz, F., de Groote, D. & Descamps-Latscha, B. Soluble CD23 potentiates interleukin-1-induced secretion of interleukin-6 and interleukin-1 receptor antagonist by human monocytes. Eur. J. Immun. 24, 1869−1873 (1994).
6. Armant, M., Ishihara, H., Rubio, M., Delespesse, G. & Sarfati, M. Regulation of cytokine production by soluble CD23: Costimulation of interferon gamma secretion and triggering of tumor necrosis factor a release. J. exp. Med. 180, 1005−1011 (1994).
7. Bansal, A.S., Oilier, W., Marsh, M.N., Pumphrey, R.S. & Wilson, P.B. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 79, 285−289 (1993).
8. Hellen, E.A., Rowlands, D.C., Hansel, T.T., Kitas, G.D. & Crocker, J. Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis. J. clin. Pathol. 44, 293−296 (1991).
9. Chomarat, P., Briolay, J., Banchereau, J. & Miossec, P. Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum. 36, 234−242 (1993).
10. Bansal, A. et al. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus. Clin. exp. Immun. 89, 452−455 (1992).
11. Rezonzew, R. & Newkirk, M.M. Impaired release of sCD23 by activated B-cells from RA patients. Clin. Immunol. Immunopathol. 71, 156−163 (1994).
12. Bansal, A.S. et al. Increased levels of sCD23 in rheumatoid arthritis are related to disease status. Clin. exp. Rheumatol. 12, 281−285 (1994).
13. Brennan, F.M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244−247 (1989).
14. Feldmann, M. et al. Cytokine assays: Role in evaluation of the pathogenesis of autoimmunity. Immunol. Rev. 119, 105−123 (1991).
15. Brennan, F.M., Maini, R.N. & Feldmann, M. TNF alpha—A pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31, 293−298 (1992).
16. Chu, C.Q., Field, M., Feldmann, M. & Maini, R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125−1132 (1991).
17. Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor-alpha. Arthritis Rheum. 36, 1681−1690 (1993).
18. Williams, R.O., Feldmann, M. & Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. natn. Acad. Sci. U.S.A. 89, 9784−9788 (1992).
19. Piguet, P.F. et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77, 510−514 (1992).
20. Wooley, P.H., Dutcher, J., Widmer, M.B. & Gillis, S. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immun. 151, 6602−6607 (1993).
21. Wooley, P.H. et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36, 1305−1314 (1993).
22. Van den Berg, W.B., Joosten, L.A.B., Helsen, M. & van de Loo, F.A.J. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. exp. Immun. 95, 237−243 (1994).
23. Field, M., Chu, C., Feldmann, M. & Maini, R.N. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol. Int. 11, 45−50 (1991).
24. Wendling, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20, 259−262 (1993).
25. Stuart, J.M., Townes, A.S. & Kang, A.H. Collagen autoimmune arthritis. Annu. Rev. Immun. 2, 199−218 (1984).
26. Trentham, D.E. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum. 25, 911−916 (1982).
27. Flores-Romo, L. et al. Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. Science 261, 1038−1041 (1993).
28. Wooley, P.H. et al. Type II collagen-induced arthritis in mice. HI. Suppression of arthritis by using monoclonal and polyclonal anti-la antisera. J. Immun. 134, 2366−2374 (1985).
29. Rao, M., Lee, W.T. & Conrad, D.H. Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE. J. Immun. 138, 1845−1851 (1987).
30. Plater-Zyberk, C., Taylor, P.C., Blaylock, M.G. & Maini, R.N. Anti-CD5 therapy decreases severity of established disease in collagen type Il-induced arthritis in DBA/1 mice. Clin. exp. Immun. 98, 442−447 (1994).
31. Aubry, J.P., Pochon, S., Graber, P., Jansen, K.U. & Bonnefoy, J.Y. CD21 is a lig-and for CD23 and regulates IgE production. Nature 358, 505−507 (1992).
32. Marcelletti, J.F., Ohara, J. & Katz, D.H. Collagen-induced arthritis in mice. Relationship of collagen-specific and total IgE synthesis to disease. J. Immun. 147, 4185−4191 (1991).

	Top

	Top